M
Mdoloris
Advanced pain monitoring devices and technologies for personalized analgesia management in clinical settings
About Mdoloris
MDoloris Medical Systems specializes in developing advanced pain monitoring devices and technologies aimed at enhancing patient care and safety. The company operates in the medical technology market, focusing on both conscious and unconscious patients across various clinical settings, including operating rooms (OR) and intensive care units (ICU). MDoloris' core product, the ANI (Analgesia Nociception Index) technology, measures the Autonomic Nervous System to help clinicians monitor the balance between analgesia and nociception, thereby improving pain management. The company collaborates with global medical technology leaders like Masimo to integrate its ANI technology into broader monitoring platforms, such as the ANI MOC 9 module within the ROOT monitor platform. This integration allows for more precise treatment options, ensuring better patient outcomes. MDoloris generates revenue through the sale of its monitoring devices and technology modules, targeting hospitals, clinics, and healthcare providers worldwide. The company's business model is centered around continuous innovation and collaboration to provide state-of-the-art solutions for pain management.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Loos, France
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 57.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2018 | $9.9M | $40M | Siparex · Seventure Partners | — |
| SERIES A✓Equity / VC | Feb 2016 | $3.3M | $13M | Siparex | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Mdoloris is 650 monthly website visits, up 18.2% over the last three months. Mdoloris's team declined 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Siparex
Series A1 investor entered at this stage
Seventure Partners
Other known investors6 additional known investors
Eurasanté
Finorpa
Finovam- GTGabrielle THOMAS
Guilhem De Vregille
XAnge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mdoloris on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mdoloris’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.